WO2008009855A3 - Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée - Google Patents

Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée Download PDF

Info

Publication number
WO2008009855A3
WO2008009855A3 PCT/FR2007/051682 FR2007051682W WO2008009855A3 WO 2008009855 A3 WO2008009855 A3 WO 2008009855A3 FR 2007051682 W FR2007051682 W FR 2007051682W WO 2008009855 A3 WO2008009855 A3 WO 2008009855A3
Authority
WO
WIPO (PCT)
Prior art keywords
acne
treatment
sc4mol
hyperseborrhoea
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/051682
Other languages
English (en)
Other versions
WO2008009855A2 (fr
Inventor
Fernand Labrie
Mohamed El-Alfy
Van Luu-The
Ezequiel L Calvo
Jerome Aubert
Isabelle Carlavan
Sophie Deret
Johannes Voegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to CA002656839A priority Critical patent/CA2656839A1/fr
Priority to EP07823601A priority patent/EP2046974A2/fr
Publication of WO2008009855A2 publication Critical patent/WO2008009855A2/fr
Publication of WO2008009855A3 publication Critical patent/WO2008009855A3/fr
Anticipated expiration legal-status Critical
Priority to US12/320,170 priority patent/US20100021892A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne une méthode in vitro de criblage de composés candidats pour le traitement préventif ou curatif de l'acné, comprenant la détermination de la capacité d'un composé à moduler l'expression ou l'activité de la C-4 méthyl stérol oxydase (SC4MOL), ainsi que l'utilisation de modulateurs de l'expression ou de l'activité de cette enzyme pour le traitement de l'acné ou des désordres cutanés associés à une hyperséborrhée. L'invention concerne aussi des méthodes de diagnostic ou pronostic in vitro de ces pathologies.
PCT/FR2007/051682 2006-07-19 2007-07-18 Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée Ceased WO2008009855A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002656839A CA2656839A1 (fr) 2006-07-19 2007-07-18 Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee
EP07823601A EP2046974A2 (fr) 2006-07-19 2007-07-18 Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée
US12/320,170 US20100021892A1 (en) 2006-07-19 2009-01-21 Modulators of SC4MOL for treating acne or hyperseborrhea

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0653028A FR2903999B1 (fr) 2006-07-19 2006-07-19 Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee
FR0653028 2006-07-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/320,170 Continuation US20100021892A1 (en) 2006-07-19 2009-01-21 Modulators of SC4MOL for treating acne or hyperseborrhea

Publications (2)

Publication Number Publication Date
WO2008009855A2 WO2008009855A2 (fr) 2008-01-24
WO2008009855A3 true WO2008009855A3 (fr) 2008-04-10

Family

ID=37698074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051682 Ceased WO2008009855A2 (fr) 2006-07-19 2007-07-18 Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée

Country Status (5)

Country Link
US (1) US20100021892A1 (fr)
EP (1) EP2046974A2 (fr)
CA (1) CA2656839A1 (fr)
FR (1) FR2903999B1 (fr)
WO (1) WO2008009855A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938333A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de cidea dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938338B1 (fr) * 2008-11-13 2012-10-05 Galderma Res & Dev Modulateurs de l'acetyl-coenzyme a acyltransferase 1 ou 2 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938342A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Ciblage de modulateurs de ces1 et/ou ces3 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938341A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
JP5990888B2 (ja) * 2011-09-29 2016-09-14 公立大学法人 富山県立大学 ヒト由来メチルステロール酸化酵素を生産する組換体及びその利用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679521A (en) * 1990-04-30 1997-10-21 Board Of Regents, The University Of Texas System Steroid 5A-reductases
WO2001056556A2 (fr) * 2000-02-02 2001-08-09 Warner-Lambert Company Doubles inhibiteurs de la synthese d'ester de choslesteryle et d'ester de cire utilises dans le traitement des troubles des glandes sebacees
US6278038B1 (en) * 1992-04-10 2001-08-21 Oregon Health And Science University Mammalian melanocortin receptors and uses
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6479733B1 (en) * 1998-11-13 2002-11-12 E. I. Du Pont De Nemours And Company Sterol metabolism enzymes
US6794137B2 (en) * 2000-09-08 2004-09-21 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
BR0209510A (pt) * 2001-05-09 2006-02-07 Univ Cleveland Hospitals Conjunto de genes marcadores, método para avaliar os efeitos protetores reparadores e/ou terapêuticos à radiação ultravioleta de um composto ou material, composto ou material tendo efeitos protetores, reparadores ou terapêuticos da radiação ultravioleta, métodos para melhorar e/ou tratar, para reverter e/ou reparar pele fotoavariada ou fotoenvelhecida, e para avaliar se uma substância pode reparar ou reverter os efeitos de fotoavaria ou fotoenvelhecimento relacionados com à exposição à radiação uv, substância ou material tendo efeitos reparadores ou de reversão da fotoavaria ou fotoenvelhecimento, composição ou formulação, formulação anti-fotoavaria ou anti-fotoenvelhecimento fotoprotetora ou terapêutica, métodos para avaliar a avaria na pele ou um substituto de pele induzida por radiação ultravioleta, em seguida à exposição à radiação uv, para prevenir pele fotoenvelhecida ou fotoavariada, para identificar ou selecionar indivìduos que são susceptìveis ou altamente sensìveis à fotoavaria ou fotoenvelhecimento da pele, em seguida à exposição à radiação uv, e, kit para avaliar as propiedades de fotoavaria ou fotoenvelhecimento de uma substância

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679521A (en) * 1990-04-30 1997-10-21 Board Of Regents, The University Of Texas System Steroid 5A-reductases
US6278038B1 (en) * 1992-04-10 2001-08-21 Oregon Health And Science University Mammalian melanocortin receptors and uses
WO2001056556A2 (fr) * 2000-02-02 2001-08-09 Warner-Lambert Company Doubles inhibiteurs de la synthese d'ester de choslesteryle et d'ester de cire utilises dans le traitement des troubles des glandes sebacees
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RODRIGUEZ C. ET AL.: "Modulation of ERG25 expression by LDL in vascular cells.", CARDIOVASCULAR RESEARCH, vol. 58, no. 1, 1 April 2003 (2003-04-01), pages 178 - 185, XP004722317, ISSN: 0008-6363 *
SINGH D.K. ET AL.: "Inhibition of sterol 4 alpha-methyl oxidase is the principal mechanism by which garlic decreases cholesterol synthesis.", J. NUTRITION, vol. 136, no. 3, Suppl. S, March 2006 (2006-03-01), pages 759S - 764S, XP001248470, ISSN: 0022-3166 *

Also Published As

Publication number Publication date
FR2903999B1 (fr) 2008-09-05
EP2046974A2 (fr) 2009-04-15
FR2903999A1 (fr) 2008-01-25
WO2008009855A2 (fr) 2008-01-24
CA2656839A1 (fr) 2008-01-24
US20100021892A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2009059150A3 (fr) Biomarqueurs de la stéatose hépatique et procédés les utilisant
WO2011015944A3 (fr) Utilisation d'adn libre en tant que prédicteur précoce de la gravité d'une pancréatite aiguë
WO2009044173A3 (fr) Procédés de traitement du cancer à l'aide d'inhibiteurs de la voie de notch
WO2009100105A3 (fr) Inhibiteurs d'isoformes oncogènes et leurs utilisations
WO2009124330A3 (fr) Traitement de maladies tumorales
WO2012006391A3 (fr) Modulateurs de sirt5 et essais pour les cribler
IL185998A0 (en) Methods for diagnosis and treatment of processing difficulties, integration problems, imbalances and abnormal postures
WO2008009856A3 (fr) Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée
WO2007134028A3 (fr) Biomarqueurs pour la dépression et méthodes d'utilisation de ceux-ci
WO2008009855A3 (fr) Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée
WO2005074985A3 (fr) Methodes de modulation de cd200
WO2008009859A3 (fr) Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée
WO2007101063A3 (fr) Traitement de troubles liés au développement
WO2008009857A3 (fr) Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation
WO2008009854A3 (fr) Modulateurs du transporteur abcd3 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008070552A3 (fr) Inhibiteurs de la protéine tyrosine phosphatase permettant de favoriser l'hypertrophie cardiaque physiologique
WO2008009858A3 (fr) Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée
WO2007038264A3 (fr) Methodes associees a gapr-1
WO2007083287A3 (fr) Procédé d'essai permettant d'évaluer l'irritation de la peau
WO2008012692A3 (fr) Test d'efficacité des inhibiteurs d'histone déacétylase
WO2008009852A3 (fr) Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée
WO2009004247A3 (fr) Inhibiteurs de tace dans le traitement de l'acne
WO2006009950A3 (fr) Genes aldo utilises comme modificateurs de la voie igf et procedes d'utilisation
WO2007140308A3 (fr) Méthodes de criblage de modulateurs trpm4 de la sécrétion d'insuline
WO2009135910A3 (fr) Modulateurs de mcam dans le traitement de l'acné, de dermatite séborrhéique ou d'hyperséborrhée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823601

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007823601

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2656839

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU